Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
37.05
-0.79 (-2.09%)
At close: Sep 18, 2026, 4:00 PM EDT
37.63
+0.58 (1.57%)
After-hours: Sep 18, 2026, 7:37 PM EDT
Cue Biopharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Cue Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $90.5. The average 1-year stock price forecast is 144.26% higher than the current stock price, while the lowest is $66 (+78.14%) and the highest is $115 (+210.39%).
Price Target: $90.5 (+144.26%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cue Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Initiates $83 | Buy | Initiates | $83 | +124.02% | Sep 18, 2026 |
Financial Forecast
Revenue This Year
16.63M
from 27.47M
Decreased by -39.45%
Revenue Next Year
5.00M
from 16.63M
Decreased by -69.94%
EPS This Year
-14.40
EPS Next Year
-12.60
from -14.40
EPS and Forward PE are based on non-GAAP adjusted numbers.